Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
For the full year FY25, net profit soared 12x to Rs 345 crore
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
AstraZeneca Pharma India discontinues manufacturing of Imdur
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Subscribe To Our Newsletter & Stay Updated
